[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Sasso FC, Carbonara O, Di Micco P, Coppola L, Torella R, Niglio A: A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy. Br J Clin Pharmacol; 2003 Aug;56(2):238-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy.
  • [MeSH-major] Antiviral Agents / adverse effects. Hepatitis C, Chronic / drug therapy. Interferon Type I / adverse effects. Polyendocrinopathies, Autoimmune / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1997 Jan 30;336(5):347-56 [9011789.001]
  • [Cites] Lancet. 1995 May 20;345(8960):1305 [7746073.001]
  • [Cites] Diabet Med. 2001 Apr;18(4):329-32 [11437866.001]
  • [Cites] Gastroenterology. 1992 Jun;102(6):2155-60 [1587439.001]
  • [Cites] Diabetes Res Clin Pract. 1994 Feb;23(1):33-6 [8013261.001]
  • (PMID = 12895200.001).
  • [ISSN] 0306-5251
  • [Journal-full-title] British journal of clinical pharmacology
  • [ISO-abbreviation] Br J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon Type I; 0 / Recombinant Proteins
  • [Other-IDs] NLM/ PMC1884279
  •  go-up   go-down


2. Fujioka T, Honda M, Yoshizaki T, Ogawa M, Matsuno H, Shimokawa K, Koyama K: A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-α plus ribavirin treatment for chronic hepatitis C. Intern Med; 2010;49(18):1987-90
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-α plus ribavirin treatment for chronic hepatitis C.
  • We report a case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon (PEG-IFN)-alpha plus ribavirin treatment for chronic hepatitis C.
  • Because Graves' disease remitted, PEG-IFN-alpha plus ribavirin treatment was started for chronic hepatitis C.
  • She was examined because of complaints of general fatigue, weight loss, and palpitations after 24 weeks of the treatment.
  • She was diagnosed with a recurrence of Graves' disease, and methimazole treatment was started.
  • She was diagnosed with type 1 diabetes with ketosis, and insulin treatment was started.
  • Graves' disease and type 1 diabetes are often complicated, and the coincidental occurrence of these 2 diseases is known as autoimmune polyglandular syndrome type III.
  • However, only a few cases have shown that these diseases occur after IFN treatment.
  • [MeSH-major] Diabetes Mellitus, Type 1 / chemically induced. Graves Disease / chemically induced. Hepatitis C, Chronic / drug therapy. Interferon-alpha / adverse effects. Polyethylene Glycols / adverse effects. Ribavirin / adverse effects
  • [MeSH-minor] Drug Therapy, Combination. Female. Humans. Middle Aged. Polyendocrinopathies, Autoimmune / chemically induced. Polyendocrinopathies, Autoimmune / complications. Polyendocrinopathies, Autoimmune / diagnosis. Recombinant Proteins. Secondary Prevention. Treatment Outcome

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Graves' Disease.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847504.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 30IQX730WE / Polyethylene Glycols; 49717AWG6K / Ribavirin; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


3. Bakrac M, Jurisic V, Kostic T, Popovic V, Pekic S, Kraguljac N, Colovic M: Pure red cell aplasia associated with type I autoimmune polyglandular syndrome-successful response to treatment with mycophenolate mofetil: case report and review of literature. J Clin Pathol; 2007 Jun;60(6):717-20
Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure red cell aplasia associated with type I autoimmune polyglandular syndrome-successful response to treatment with mycophenolate mofetil: case report and review of literature.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Mycophenolic Acid / analogs & derivatives. Polyendocrinopathies, Autoimmune / complications. Red-Cell Aplasia, Pure / drug therapy

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Nephrol. 2000 Mar;14(3):195-7 [10752755.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3639-46 [16804051.001]
  • [Cites] Clin Transplant. 2001;15 Suppl 6:36-40 [11903384.001]
  • [Cites] Clin Nephrol. 2003 Aug;60(2):119-24 [12940614.001]
  • [Cites] Blood. 1990 Feb 15;75(4):941-50 [2105751.001]
  • [Cites] N Engl J Med. 1990 Jun 28;322(26):1829-36 [2348835.001]
  • [Cites] Science. 1995 Apr 21;268(5209):403-5 [7716542.001]
  • [Cites] N Engl J Med. 1996 Mar 7;334(10):630-3 [8592526.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4831-8 [8639856.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):393-8 [9398839.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1049-55 [9543115.001]
  • [Cites] N Engl J Med. 1999 Jan 28;340(4):278-84 [9920952.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):844-52 [10084559.001]
  • [Cites] Br J Haematol. 2005 May;129(4):534-8 [15877736.001]
  • [Cites] Transplant Proc. 2005 Sep;37(7):3226-9 [16213354.001]
  • [Cites] Transplantation. 2005 Oct 15;80(2 Suppl):S181-90 [16251851.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Feb;54(2):211-7 [11207636.001]
  • (PMID = 17220208.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / APECED protein; 0 / Immunosuppressive Agents; 0 / Transcription Factors; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid
  • [Number-of-references] 17
  • [Other-IDs] NLM/ PMC1955055
  •  go-up   go-down


Advertisement
4. Sünkel S, Wichmann-Hesse A, Gärtner R, Hesse G: [Increasing pigmentation in Schmidt syndrome (polyglandular autoimmune syndrome type II]. Hautarzt; 2001 Oct;52(10 Pt 2):974-6
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Increasing pigmentation in Schmidt syndrome (polyglandular autoimmune syndrome type II].
  • This confirmed the diagnosis of Schmidt syndrome as part of polyglandular autoimmune disease (PGAS) type II.
  • After another 18 months of treatment with hormone substitution of L-thyroxine and hydrocortisone, the hyperpigmentation resolved and the hyperpigmented nevi decreased in number.
  • [MeSH-minor] Addison Disease / complications. Adolescent. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Biopsy. Drug Therapy, Combination. Fludrocortisone / administration & dosage. Fludrocortisone / therapeutic use. Follow-Up Studies. Humans. Hydrocortisone / administration & dosage. Hydrocortisone / therapeutic use. Male. Nevus, Pigmented / complications. Nevus, Pigmented / pathology. Skin / pathology. Thyroiditis, Autoimmune / complications. Thyroxine / administration & dosage. Thyroxine / therapeutic use. Time Factors

  • Hazardous Substances Data Bank. FLUDROCORTISONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11715397.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; Q51BO43MG4 / Thyroxine; U0476M545B / Fludrocortisone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


5. Bassotti G, Di Sarra D, Pietrobono D, Schiaffini R, Battocletti T, D'Amico T, Gargiulo P: Polyglandular autoimmune endocrine insufficiency complicated by severe osteoporosis. Minerva Endocrinol; 2006 Dec;31(4):289-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyglandular autoimmune endocrine insufficiency complicated by severe osteoporosis.
  • In literature different cases of polyglandular autoimmune type II syndrome (PGA II) are reported, where Addison's disease is associated with gonadal insufficiency.
  • Between 1988 and 1997 the patient developed a progressive insufficiency of other endocrine glands, leading to the classic feature of PGA II.
  • They would directly act on the bony tissue, independently from oestrogens peripheral conversion, thus producing a stimulant effect on the bone formation.
  • A new therapeutical approach, in case of osteoporosis, is today represented by DHEA replacement therapy in women showing low hormone levels.
  • [MeSH-major] Dehydroepiandrosterone / therapeutic use. Osteoporosis, Postmenopausal / etiology. Polyendocrinopathies, Autoimmune / complications
  • [MeSH-minor] Addison Disease / etiology. Adult. Asthenia / etiology. Bone Density / drug effects. Female. Gonadal Steroid Hormones / deficiency. Hormone Replacement Therapy. Humans. Hyperglycemia / drug therapy. Hyperglycemia / etiology. Insulin / therapeutic use

  • Genetic Alliance. consumer health - Osteoporosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17213795.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng; ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 0 / Insulin; 459AG36T1B / Dehydroepiandrosterone
  •  go-up   go-down


6. Manz B, Scholz GH, Willgerodt H, Haustein UF, Nenoff P: Autoimmune polyglandular syndrome (APS) type 1 and candida onychomycosis. Eur J Dermatol; 2002 May-Jun;12(3):283-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune polyglandular syndrome (APS) type 1 and candida onychomycosis.
  • In addition, malabsorption syndrome and signs of pernicious anaemia occurred.
  • The onychomycosis totally improved under systemic treatment with fluconazole (Diflucan), endocrine and organ failure with replacement therapy.
  • The autoimmune polyglandular syndrome (APS 1) is a rare autosomal recessive inherited disease.
  • Chronic mucocutaneous candidiasis (CMC) generally presents very early in life and is the most frequent of the three main diseases of APS type 1 (chronic hypoparathyroidism, autoimmune Addison's disease).
  • It can be considered as a precocious marker of APS type 1.
  • [MeSH-minor] Adult. Antifungal Agents / therapeutic use. Candidiasis, Chronic Mucocutaneous / complications. Female. Fluconazole / therapeutic use. Hand Dermatoses / complications. Hand Dermatoses / drug therapy. Humans

  • Genetic Alliance. consumer health - Autoimmune Polyglandular Syndrome Type 1.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11978574.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antifungal Agents; 8VZV102JFY / Fluconazole
  •  go-up   go-down


7. Owecki M, Waśko R, Sowiński J: [Autoimmune polyglandular syndrome type 2 and osteoporosis in a 69 years old patient]. Pol Arch Med Wewn; 2003 Nov;110(5):1335-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autoimmune polyglandular syndrome type 2 and osteoporosis in a 69 years old patient].
  • We present a case of a 69 year old female with autoimmune polyglandular syndrome type 2 or Schmidt's syndrome.
  • The syndrome consists of primary autoimmune adrenocortical insufficiency (Addison's disease), autoimmune hypothyroidism, and type 1 diabetes.
  • After substitutional pharmacotherapy was implemented, the patient was discharged in good health.
  • Possible correlation between bone metabolism disorders and autoimmune polyglandular syndrome needs further investigation.


8. Berger JR, Weaver A, Greenlee J: Neurologic consequences of autoimmune polyglandular syndrome type 1. Neurology; 2008 Jun 3;70(23):2248-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurologic consequences of autoimmune polyglandular syndrome type 1.
  • BACKGROUND: Autoimmune polyglandular syndrome type 1 (APS-1) is a rare autosomal recessive disorder that is chiefly characterized by polyendocrinopathy, chronic mucocutaneous candidiasis, and ectodermal dystrophy.
  • Miller Fisher syndrome, from which she had fully recovered.
  • CONCLUSIONS: Autoimmune neurologic disease may develop with autoimmune polyglandular syndrome type 1.
  • [MeSH-minor] Adult. Animals. Candidiasis, Chronic Mucocutaneous / complications. Candidiasis, Chronic Mucocutaneous / diagnosis. Candidiasis, Chronic Mucocutaneous / drug therapy. Female. Humans. Immunoglobulins, Intravenous / therapeutic use. Miller Fisher Syndrome / complications. Miller Fisher Syndrome / diagnosis. Miller Fisher Syndrome / drug therapy. Rats. Spinocerebellar Degenerations / complications. Spinocerebellar Degenerations / diagnosis. Spinocerebellar Degenerations / drug therapy. Syndrome

  • Genetic Alliance. consumer health - Autoimmune Polyglandular Syndrome Type 1.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Neurology. 2008 Jul;71(4):304. Wahlen, George E [removed]
  • (PMID = 18519874.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


9. Graves L 3rd, Klein RM, Walling AD: Addisonian crisis precipitated by thyroxine therapy: a complication of type 2 autoimmune polyglandular syndrome. South Med J; 2003 Aug;96(8):824-7
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Addisonian crisis precipitated by thyroxine therapy: a complication of type 2 autoimmune polyglandular syndrome.
  • Rarely, it may occur in combination with autoimmune failure of other endocrine glands (autoimmune polyendocrinopathy syndrome type 2, previously known as Schmidt's syndrome).
  • Clinicians should have a high index of suspicion for this condition in patients with Addison's disease, those with a family history of autoimmune endocrine gland failure, patients with one autoimmune endocrine disease who develop nonspecific or serious illness, and patients with type 1 diabetes mellitus whose insulin requirements drop without obvious explanation.
  • [MeSH-major] Addison Disease / etiology. Hormone Replacement Therapy / adverse effects. Hypothyroidism / complications. Hypothyroidism / drug therapy. Iodide Peroxidase. Iron-Binding Proteins. Polyendocrinopathies, Autoimmune / complications. Polyendocrinopathies, Autoimmune / drug therapy. Thyroxine / adverse effects
  • [MeSH-minor] Adrenocorticotropic Hormone. Adult. Autoantibodies / blood. Autoantigens / immunology. B-Lymphocytes / immunology. Diagnosis, Differential. Drug Monitoring. Female. Humans. Hydrocortisone / blood. Male. Precipitating Factors. T-Lymphocytes / immunology. Thyrotropin / blood. Weight Loss

  • Genetic Alliance. consumer health - Autoimmune Polyglandular Syndrome Type 2.
  • MedlinePlus Health Information. consumer health - Addison Disease.
  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] South Med J. 2004 Apr;97(4):424 [15108845.001]
  • (PMID = 14515930.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Iron-Binding Proteins; 0 / anti-thyroglobulin; 9002-60-2 / Adrenocorticotropic Hormone; 9002-71-5 / Thyrotropin; EC 1.11.1.7 / TPO protein, human; EC 1.11.1.8 / Iodide Peroxidase; Q51BO43MG4 / Thyroxine; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


10. Lipowsky C, Schorl-Schweikardt BA, Kehl O, Brändle M: [19-year-old patient with adrenal cortex insufficiency--only the tip of the iceberg. Polyendocrine autoimmune syndrome type II (Schmidt syndrome)]. Praxis (Bern 1994); 2008 Jan 23;97(2):77-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [19-year-old patient with adrenal cortex insufficiency--only the tip of the iceberg. Polyendocrine autoimmune syndrome type II (Schmidt syndrome)].
  • [Transliterated title] 19-Jährige mit Nebennierenrindeninsuffizienz--nur die Spitze des Eisbergs. Polyglandulares Autoimmunsyndrom Typ II (Schmidt-Syndrom).
  • We report on a 19-year-old woman with polyglandular autoimmune syndrome type II (APS II).
  • In patients and their relatives, who have autoimmune disorders, a search for autoimmune polyglandular syndrome is crucial.
  • Therapy of APS II consists of hormone replacement therapy, but thyroxin replacement may induce life-threatening adrenal failure in a patient with untreated Addison's disease.
  • [MeSH-minor] Adrenocorticotropic Hormone / blood. Adult. Cortisone / analogs & derivatives. Cortisone / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Fatigue / etiology. Female. Fludrocortisone / therapeutic use. Genetic Predisposition to Disease / genetics. Humans. Hydrocortisone / blood. Muscle Weakness / etiology. Thyroiditis, Autoimmune / diagnosis. Thyroiditis, Autoimmune / drug therapy. Thyroiditis, Autoimmune / genetics. Thyroxine / therapeutic use. Weight Loss

  • MedlinePlus Health Information. consumer health - Addison Disease.
  • Hazardous Substances Data Bank. FLUDROCORTISONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303665.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 883WKN7W8X / cortisone acetate; 9002-60-2 / Adrenocorticotropic Hormone; Q51BO43MG4 / Thyroxine; U0476M545B / Fludrocortisone; V27W9254FZ / Cortisone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


11. Papi G, Salvatori R, Ferretti G, Roti E: Thyroid hemiagenesis and autoimmune polyglandular syndrome type III. J Endocrinol Invest; 2003 Nov;26(11):1160-1
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid hemiagenesis and autoimmune polyglandular syndrome type III.
  • [MeSH-minor] Adult. Female. Humans. Hypothyroidism / complications. Hypothyroidism / drug therapy. Radionuclide Imaging. Thyroxine / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Pediatr. 2000 Jun;159(6):456-8 [10867854.001]
  • [Cites] J Womens Health (Larchmt). 2003 Jun;12(5):513-20 [12869299.001]
  • [Cites] Endocrinol Metab Clin North Am. 2002 Jun;31(2):431-9, viii [12092459.001]
  • [Cites] Surg Today. 1994;24(2):164-9 [8054799.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Feb;52(2):247-51 [7462390.001]
  • (PMID = 15008258.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] Q51BO43MG4 / Thyroxine
  •  go-up   go-down


12. Carboni I, Soda R, Bianchi L, Chimenti S: Chronic mucocutaneous candidiasis and alopecia areata as cutaneous expressions of autoimmune polyglandular syndrome type I. Acta Derm Venereol; 2002;82(1):68-9
Genetic Alliance. consumer health - Alopecia Areata.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic mucocutaneous candidiasis and alopecia areata as cutaneous expressions of autoimmune polyglandular syndrome type I.
  • [MeSH-minor] Adult. Antifungal Agents / administration & dosage. Biopsy, Needle. Drug Therapy, Combination. Humans. Male. Prognosis. Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12013209.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


13. Fink H, Hintze G: [Autoimmune thyroiditis (Hashimoto's thyroiditis): current diagnostics and therapy]. Med Klin (Munich); 2010 Jul;105(7):485-93
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autoimmune thyroiditis (Hashimoto's thyroiditis): current diagnostics and therapy].
  • [Transliterated title] Die Autoimmunthyreoiditis (Hashimoto-Thyreoiditis): aktuelle diagnostik und therapie.
  • Autoimmune thyroiditis is frequently associated with autoimmune disease of other organs, such as vitiligo, Addison's disease, diabetes mellitus type 1, often in the sense of polyglandular syndrome 2.
  • [MeSH-major] Hashimoto Disease / diagnosis. Hashimoto Disease / drug therapy
  • [MeSH-minor] Adult. Autoantibodies / blood. Comorbidity. Diabetes Mellitus, Type 1 / diagnosis. Diabetes Mellitus, Type 1 / drug therapy. Diabetes Mellitus, Type 1 / immunology. Dose-Response Relationship, Drug. Female. Humans. Hypothyroidism / diagnosis. Hypothyroidism / drug therapy. Hypothyroidism / immunology. Infertility, Female / diagnosis. Infertility, Female / drug therapy. Infertility, Female / immunology. Insulin / therapeutic use. Iodide Peroxidase / immunology. Male. Middle Aged. Pregnancy. Thyroglobulin / immunology. Thyroid Function Tests. Thyroxine / therapeutic use. Ultrasonography

  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2003 Oct;24(5):694-717 [14570752.001]
  • [Cites] Eur J Endocrinol. 1998 Jul;139(1):23-8 [9703374.001]
  • [Cites] Thyroid. 2009 Jan;19(1):9-12 [19021461.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Mar;94(3):833-9 [19088156.001]
  • [Cites] Schweiz Med Wochenschr. 1998 Nov 28;128(48):1902-5 [9879618.001]
  • [Cites] Internist (Berl). 2010 May;51(5):568,570-3 [20372870.001]
  • [Cites] Hum Reprod. 1991 Mar;6(3):338-45 [1955537.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):389-93 [12656658.001]
  • [Cites] Arch Intern Med. 2008 Aug 11;168(15):1657-63 [18695079.001]
  • [Cites] Am J Med. 2010 Feb;123(2):183.e1-9 [20103030.001]
  • [Cites] Endocr Rev. 2008 Feb;29(1):76-131 [17991805.001]
  • [Cites] Med Klin (Munich). 2006 Aug 15;101(8):645-52; quiz 653-4 [16896571.001]
  • [Cites] Thyroid. 2005 Oct;15(10):1177-81 [16279852.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4809-16 [17003083.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):581-5; discussion 586-7 [15643019.001]
  • [Cites] Internist (Berl). 2006 Jul;47(7):729-46; quiz 747 [16680414.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2592-9 [16670166.001]
  • [Cites] Eur J Endocrinol. 2010 Mar;162(3):579-85 [20007334.001]
  • [Cites] Endocrinology. 1986 May;118(5):1977-81 [3754509.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Sep;71(3):661-9 [2168432.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Feb;95(2):953-62 [20016049.001]
  • [Cites] Nuklearmedizin. 1999;38(5):144-9 [10488481.001]
  • (PMID = 20676951.001).
  • [ISSN] 1615-6722
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Insulin; 9010-34-8 / Thyroglobulin; EC 1.11.1.8 / Iodide Peroxidase; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


14. Moloney FJ, Hughes R, O'Shea D, Kirby B: Type I immediate hypersensitivity reaction to cyanocobalamin but not hydroxycobalamin. Clin Exp Dermatol; 2008 Jul;33(4):412-4
Hazardous Substances Data Bank. CYANOCOBALAMIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type I immediate hypersensitivity reaction to cyanocobalamin but not hydroxycobalamin.
  • We report a case of a 42-year-old woman with a background of autoimmune polyglandular syndrome, who developed a type I immediate hypersensitivity reaction to intramuscular cyanocobalamin.
  • [MeSH-major] Drug Hypersensitivity / etiology. Hypersensitivity, Immediate / chemically induced. Vitamin B 12 / adverse effects. Vitamin B 12 Deficiency / drug therapy. Vitamin B Complex / adverse effects
  • [MeSH-minor] Adult. Anemia, Pernicious / drug therapy. Female. Humans. Hydroxocobalamin / administration & dosage. Hydroxocobalamin / adverse effects. Injections, Intramuscular. Treatment Outcome

  • MedlinePlus Health Information. consumer health - B Vitamins.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. HYDROXOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18498413.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 12001-76-2 / Vitamin B Complex; P6YC3EG204 / Vitamin B 12; Q40X8H422O / Hydroxocobalamin
  •  go-up   go-down


15. Schloot NC, Hübinger A, Scherbaum WA: [Prerenal kidney failure in type 1 diabetes mellitus]. Dtsch Med Wochenschr; 2003 Dec 5;128(49):2588-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prerenal kidney failure in type 1 diabetes mellitus].
  • Type 1 diabetes mellitus had been diagnosed when he was 13 years old, hypothyroidism was treated with L-thyroxine for 2 years.
  • Autoimmune polyglandular syndrome (APS) type II with Addison's disease, diabetes mellitus type 1 and hypothyroidism (Schmidt-Carpenter-Syndrome) were diagnosed.
  • TREATMENT AND COURSE: Initially, the patient was treated with sodium chloride 0.9% i. v. and oral sodium 5 g 4 times/day.
  • Intensified conventional insulin therapy was continued.
  • CONCLUSION: In patients with type 1 diabetes, especially in combination with associated organ-specific autoimmune diseases, autoimmune polyglandular syndrome should be considered and adequately treated with those hormones that are reduced.
  • [MeSH-major] Diabetes Mellitus, Type 1 / complications. Polyendocrinopathies, Autoimmune / diagnosis
  • [MeSH-minor] Addison Disease / blood. Addison Disease / complications. Addison Disease / diagnosis. Addison Disease / drug therapy. Adult. Anti-Inflammatory Agents / therapeutic use. Diagnosis, Differential. Fludrocortisone / therapeutic use. Humans. Hydrocortisone / therapeutic use. Hyperpigmentation. Hypotension. Hypothyroidism / blood. Hypothyroidism / complications. Hypothyroidism / diagnosis. Hypothyroidism / drug therapy. Male. Sodium Chloride / therapeutic use. Syndrome. Thyroxine / therapeutic use

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes mellitus type 1.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • Hazardous Substances Data Bank. FLUDROCORTISONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14655075.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 451W47IQ8X / Sodium Chloride; Q51BO43MG4 / Thyroxine; U0476M545B / Fludrocortisone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


16. Koch CA: Rapid increase in bone mineral density in a child with osteoporosis and autoimmune hypoparathyroidism treated with PTH 1-34. Exp Clin Endocrinol Diabetes; 2001;109(6):350-4
MedlinePlus Health Information. consumer health - Osteoporosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a 16-year-old girl with autoimmune polyglandular syndrome type 1 including hypoparathyroidism, who had osteoporosis that improved rapidly with parathyroid hormone replacement therapy.
  • Our patient developed vertebral compression fractures at age 10, shortly after hypoparathyroidism was diagnosed.
  • Several factors including decreased physical activity, total body magnesium depletion, and intermittent ketoconazole and short-term prednisone treatment, may have contributed to the development and progression of osteoporosis.
  • Therapy with synthetic human parathyroid hormone (PTH) 1-34 rapidly normalized lumbar bone mass, as assessed by DEXA.
  • [MeSH-major] Autoimmune Diseases / complications. Bone Density / drug effects. Hypoparathyroidism / complications. Osteoporosis / complications. Osteoporosis / drug therapy. Parathyroid Hormone / therapeutic use. Peptide Fragments / therapeutic use

  • Genetic Alliance. consumer health - Hypoparathyroidism.
  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Exp Clin Endocrinol Diabetes. 2002 Apr;110(2):100 [12211159.001]
  • (PMID = 11571675.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Retracted Publication
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Peptide Fragments
  •  go-up   go-down


17. Strassburg CP: Autoimmune hepatitis. Best Pract Res Clin Gastroenterol; 2010 Oct;24(5):667-82
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Key for the improvement of prognosis is a timely diagnosis before cirrhosis has developed.
  • Treatment achieves remission rates in 80% of individuals and consists of immunosuppression with corticosteroids and azathioprine.
  • A recent randomised controlled multicenter trial has added budesonide to the effective treatment options in non-cirrhotic patients and leads to a reduction of unwanted steroid side effects.
  • However, apart from the autoimmune polyglandular syndrome type 1, in which 10% of patients suffer from an autoantibody-positive autoimmune hepatitis linked to mutations of the autoimmune regulator gene, there is no clear evidence for a hereditary aetiology of this disease.
  • [MeSH-minor] Animals. Azathioprine / administration & dosage. Budesonide / administration & dosage. Diagnosis, Differential. Drug Therapy, Combination. Genetic Predisposition to Disease. Glucocorticoids / administration & dosage. Humans. Immunosuppressive Agents / administration & dosage. Liver Cirrhosis / epidemiology. Liver Transplantation. Major Histocompatibility Complex / genetics. Polyendocrinopathies, Autoimmune / genetics. Prednisone / administration & dosage. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Autoimmune Hepatitis.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20955969.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 51333-22-3 / Budesonide; MRK240IY2L / Azathioprine; VB0R961HZT / Prednisone
  •  go-up   go-down


18. Lewandowski K, Hincz P, Grzesiak M, Cajdler-Łuba A, Salata I, Wilczyński J, Lewiński A: New onset Addison's disease presenting as prolonged hyperemesis in early pregnancy. Ginekol Pol; 2010 Jul;81(7):537-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At about 8 weeks of gestation she started to vomit several times a day.
  • She was started on hydrocortisone and felt tremendously better A diagnosis of Addisons disease was made (in view of hypothyroidism as a part of Autoimmune Polyglandular Syndrome type II).
  • [MeSH-major] Addison Disease / diagnosis. Addison Disease / drug therapy. Hyperemesis Gravidarum / etiology. Pregnancy Complications / diagnosis. Pregnancy Complications / drug therapy. Pregnancy Trimester, First
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Fludrocortisone / therapeutic use. Humans. Hydrocortisone / therapeutic use. Pregnancy. Treatment Outcome


19. Bogdanos DP, Dalekos GN: Enzymes as target antigens of liver-specific autoimmunity: the case of cytochromes P450s. Curr Med Chem; 2008;15(22):2285-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Characterization of liver-specific autoantigens has given a fresh impetus to research in the pathogenesis of autoimmune liver diseases, viral-triggered and drug-induced autoimmunity affecting the liver.
  • Detection of autoantibodies against the respective antigens is carried out for diagnostic and research purposes using indirect immunofluorescence, immunoblotting, enzyme-linked immunosorbent assays, radioimmunoassay, immunoprecipitation or assays determining inhibition of enzyme activity.
  • In patients with autoimmune hepatitis, a liver disorder of unknown etiology and pathogenesis, disease-specific autoantibodies are frequently directed against drug metabolizing enzymes of phase 1, namely cytochrome P450 2D6 (CYP2D6).
  • The same and other members of these families of enzymes (CYPs) have also been described as targets of liver-specific autoimmunity in chronic hepatitis C virus (HCV)-infected patients, patients with autoimmune hepatitis as part of the autoimmune polyglandular syndrome type-1 (APS-1) and drug-induced autoimmunity.
  • Accordingly, in this review we will focus on the pathogenic role -if any- of autoimmune responses against liver-related CYPs in autoimmune hepatitis, HCV infection, APS-1 and drug-induced autoimmunity.
  • Learning more about the specificity of antibody responses against these enzymes may help us better understand the mechanisms underlying liver autoimmunity and may facilitate the development of therapeutic and preventive interventions.

  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827854691 for PMID:18781950 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18781950.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Autoantigens; 9035-51-2 / Cytochrome P-450 Enzyme System
  • [Number-of-references] 83
  •  go-up   go-down


20. Christin-Maître S: [Ovarian genes]. Gynecol Obstet Fertil; 2002 Oct;30(10):827-30
MedlinePlus Health Information. consumer health - Premature Ovarian Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian insufficiency can occur by three mechanisms: reduction in the primary follicles reserve (ataxia-telangiectasy), follicular maturation blocking (modification of the genes GDF-9 and GDF-9B, null mutation of FSH receptor gene, auto-immune polyglandular disease, PBE syndrome), or apoptosis acceleration (chemotherapy, smoking, galactosemia, Turner's syndrome).

  • MedlinePlus Health Information. consumer health - Menopause.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12478993.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 13
  •  go-up   go-down


21. Jääskeläinen J, Perheentupa J: Autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED)--a diagnostic and therapeutic challenge. Pediatr Endocrinol Rev; 2009 Dec;7(2):15-28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED)--a diagnostic and therapeutic challenge.
  • Autoimmune polyendocrinopathy - candidosis - ectodermal dystrophy (APECED), also known as autoimmune polyendocrine/polyglandular syndrome type 1 (APS1), is a rare disease caused by mutations in the autoimmune regulator (AIRE) gene pair resulting in absence of active AIRE protein, which is essential for both central and peripheral self-tolerance.
  • [MeSH-major] Adrenal Insufficiency / drug therapy. Candidiasis, Chronic Mucocutaneous / drug therapy. Hypoparathyroidism / drug therapy. Polyendocrinopathies, Autoimmune / diagnosis. Polyendocrinopathies, Autoimmune / physiopathology
  • [MeSH-minor] Adult. Autoantibodies / analysis. Biomarkers / blood. Child. Humans. Interferon Type I / antagonists & inhibitors. Mutation. Prognosis. Severity of Illness Index. Transcription Factors / genetics. Transcription Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118890.001).
  • [ISSN] 1565-4753
  • [Journal-full-title] Pediatric endocrinology reviews : PER
  • [ISO-abbreviation] Pediatr Endocrinol Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / APECED protein; 0 / Autoantibodies; 0 / Biomarkers; 0 / Interferon Type I; 0 / Transcription Factors; 0 / interferon omega 1; Autoimmune polyendocrinopathy syndrome, type 1
  •  go-up   go-down


22. Bösch D, Kurtz W: [Fatigue and icterus in a 27-year-old patient with diabetes mellitus type I]. Internist (Berl); 2006 Nov;47(11):1173-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fatigue and icterus in a 27-year-old patient with diabetes mellitus type I].
  • We report about a 27-year-old female with type I diabetes who was admitted with progressive fatigue and a sudden onset of icterus.
  • As the underlying cause, we found pernicious anemia with hemolytic activity as part of polyglandular autoimmune syndrome (PAS) type II.
  • Type I diabetes is the most frequent component of PAS II, whereas pernicious anemia is a rather rare component; however, a latent form is seen in about 12% of patients with type I diabetes.
  • Therapy for pernicious anemia consists of parenteral vitamin B(12) substitution.
  • [MeSH-major] Anemia, Pernicious / diagnosis. Anemia, Pernicious / drug therapy. Fatigue / prevention & control. Jaundice / prevention & control. Polyendocrinopathies, Autoimmune / diagnosis. Polyendocrinopathies, Autoimmune / drug therapy. Riboflavin / therapeutic use
  • [MeSH-minor] Adult. Diabetes Mellitus, Type 1. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Fatigue.
  • Hazardous Substances Data Bank. Riboflavin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):2983-92 [12843130.001]
  • [Cites] Schweiz Med Wochenschr. 1999 Jun 12;129(23):861-72 [10420442.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Sep;90(9):5254-8 [16030155.001]
  • [Cites] Br J Cancer. 1989 May;59(5):810-3 [2736218.001]
  • [Cites] Ann Med Interne (Paris). 1999 Jun;150(4):301-12 [10519018.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2068-79 [15141045.001]
  • [Cites] N Engl J Med. 1997 Nov 13;337(20):1441-8 [9358143.001]
  • (PMID = 16969670.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] TLM2976OFR / Riboflavin
  •  go-up   go-down


23. Wollina U, Schreiber G: Polyglandular autoimmune syndrome type II (Schmidt's syndrome) in patients with autoimmune connective tissue disorders. J Eur Acad Dermatol Venereol; 2003 May;17(3):371-2
MedlinePlus Health Information. consumer health - Connective Tissue Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyglandular autoimmune syndrome type II (Schmidt's syndrome) in patients with autoimmune connective tissue disorders.
  • [MeSH-major] Connective Tissue Diseases / diagnosis. Polyendocrinopathies, Autoimmune / diagnosis
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / therapeutic use. Autoimmune Diseases / complications. Autoimmune Diseases / diagnosis. Autoimmune Diseases / drug therapy. Autoimmune Diseases / pathology. Diabetes Mellitus, Type 1. Diagnosis, Differential. Female. Humans. Lupus Erythematosus, Cutaneous. Middle Aged. Steroids

  • Genetic Alliance. consumer health - Connective Tissue Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12702101.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Steroids
  •  go-up   go-down


24. Hassan G: Terbinafine effectiveness in ketoconazole-resistant mucocutaneous candidasis in polyglandular autoimmune syndrome type 1. J Assoc Physicians India; 2003 Mar;51:323
Hazardous Substances Data Bank. KETOCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Terbinafine effectiveness in ketoconazole-resistant mucocutaneous candidasis in polyglandular autoimmune syndrome type 1.
  • [MeSH-major] Antifungal Agents / therapeutic use. Candidiasis, Chronic Mucocutaneous / drug therapy. Candidiasis, Chronic Mucocutaneous / etiology. Drug Resistance, Fungal. Ketoconazole / therapeutic use. Naphthalenes / therapeutic use. Polyendocrinopathies, Autoimmune / complications. Polyendocrinopathies, Autoimmune / drug therapy
  • [MeSH-minor] Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Autoimmune Polyglandular Syndrome Type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12839367.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Naphthalenes; G7RIW8S0XP / terbinafine; R9400W927I / Ketoconazole
  •  go-up   go-down


25. Mazul-Sunko B, Resetic J, Solter M, Ivanec Z: Postoperative adrenal crisis in a patient with Schmidt syndrome (autoimmune polyglandular endocrinopathy type II). Eur J Anaesthesiol; 2004 May;21(5):416-7
Hazardous Substances Data Bank. METHIMAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative adrenal crisis in a patient with Schmidt syndrome (autoimmune polyglandular endocrinopathy type II).
  • [MeSH-minor] Adult. Anesthetics, Intravenous / adverse effects. Anesthetics, Intravenous / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Antithyroid Agents / therapeutic use. Estradiol / therapeutic use. Etomidate / adverse effects. Etomidate / therapeutic use. Female. Fentanyl / adverse effects. Fentanyl / therapeutic use. Humans. Hydrocortisone / therapeutic use. Hyperthyroidism / complications. Hyperthyroidism / drug therapy. Methimazole / therapeutic use. Thyroiditis / complications. Thyroiditis / drug therapy

  • MedlinePlus Health Information. consumer health - After Surgery.
  • Hazardous Substances Data Bank. FENTANYL .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15141804.001).
  • [ISSN] 0265-0215
  • [Journal-full-title] European journal of anaesthesiology
  • [ISO-abbreviation] Eur J Anaesthesiol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anesthetics, Intravenous; 0 / Anti-Inflammatory Agents; 0 / Antithyroid Agents; 4TI98Z838E / Estradiol; 554Z48XN5E / Methimazole; UF599785JZ / Fentanyl; WI4X0X7BPJ / Hydrocortisone; Z22628B598 / Etomidate
  •  go-up   go-down


26. Buchman AL, Rao SM: A patient with a polyglandular autoimmune syndrome involving the salivary glands, thyroid, intestine, and pancreas. Dig Dis Sci; 2004 Apr;49(4):590-3
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with a polyglandular autoimmune syndrome involving the salivary glands, thyroid, intestine, and pancreas.
  • [MeSH-major] Polyendocrinopathies, Autoimmune / drug therapy. Polyendocrinopathies, Autoimmune / pathology. Prednisone / therapeutic use
  • [MeSH-minor] Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Pancreas / pathology. Risk Assessment. Salivary Glands / pathology. Severity of Illness Index. Thyroid Gland / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 1997 Sep;24(9):1719-24 [9292794.001]
  • [Cites] Clin Rheumatol. 1983 Jun;2(2):139-43 [6331966.001]
  • [Cites] Dig Dis Sci. 1995 Jul;40(7):1561-8 [7628283.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2000 Nov;97(11):1355-63 [11215185.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Sep-Oct;13(5):1454-7 [1414842.001]
  • [Cites] Pancreas. 1999 Apr;18(3):252-8 [10206483.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):1042-6 [10201480.001]
  • [Cites] Am J Med. 1995 Nov;99(5):480-4 [7485204.001]
  • [Cites] Clin Chem. 1987 Feb;33(2 Pt 1):305-7 [2433075.001]
  • [Cites] Br J Ophthalmol. 1967 Nov;51(11):721-6 [4965427.001]
  • [Cites] Arch Intern Med. 1989 Apr;149(4):848-52 [2784958.001]
  • [Cites] Scand J Rheumatol Suppl. 1986;61:151-5 [3473625.001]
  • [Cites] Lancet. 1975 Mar 8;1(7906):550-2 [47019.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1999 May;31(4):283-7 [10425571.001]
  • [Cites] Gut. 1994 Sep;35(9):1215-8 [7959226.001]
  • [Cites] Dig Dis. 1991;9(4):210-8 [1914220.001]
  • [Cites] Nature. 1983 Jul 7-13;304(5921):73-6 [6346104.001]
  • [Cites] Am J Med. 1979 May;66(5):733-6 [443249.001]
  • [Cites] Clin Chem. 2002 Jul;48(7):1133 [12089196.001]
  • [Cites] Int J Pancreatol. 1995 Feb;17 (1):47-54 [8568334.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;966:320-6 [12114289.001]
  • (PMID = 15185862.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] VB0R961HZT / Prednisone
  •  go-up   go-down






Advertisement